A Multicenter, Randomized, Double-blind, Parallel, Active-controlled Clinical Trial With Non-inferiority Comparison to Evaluate Efficacy and Safety of Intra-articular Injection of DUROLANE® vs. ARTZ® in Treatment of Knee Osteoarthritis
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Knee Osteoarthritis
- Sponsor
- Bioventus LLC
- Enrollment
- 349
- Locations
- 7
- Primary Endpoint
- WOMAC (Western Ontario and McMaster Osteoarthritis Index) Pain Subscale Change From Baseline
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
The purpose of this study is to determine the comparative safety and efficacy of intra-articular injection of hyaluronic acid, obtained from two different sources, in the treatment of osteoarthritic pain of the knee.
Detailed Description
This is a multicenter, randomized, double blind, parallel-controlled clinical trial using a non-inferiority comparison to evaluate the efficacy and safety of an intra-articular injection of Durolane® vs Artz® in the treatment of knee osteoarthritis. Subjects will be randomized 1:1 to receive either Durolane or Artz. All subjects will be followed up for 26 weeks from the initial treatment.The screening period is expected to be up to 2 weeks in duration before the baseline visit. Each subject will provide a written informed consent and undergo a qualifying screening. Assessment at screening will include postero-anterior view of standing weight-bearing semi-flexed radiographs of the study knee. The osteoarthritis changes of the study knee will be graded 0,1,2,3 or 4 according to the Kellgren-Lawrence radiographic scoring criteria. Radiographic assessment will be made by an assigned and well trained investigator at each study center. The study knee and contralateral knee will use the Likert WOMAC 5-point scoring for pain assessment. Physical examination of the knees and vital signs will be performed (this examination will be repeated at end).
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subject (female or male) 40-80 years of age, inclusive
- •Documented diagnosis of mild to moderate osteoarthritis of the study knee that fulfil the ACR(American College of Rheumatology) criteria
- •Radiographic evidence of osteoarthritis in the study knee (Kellgren Lawrence radiographic score is 2 or 3)
Exclusion Criteria
- •Clinically apparent tense effusion of the study knee on examination determined by either a positive bulge sign or positive ballottement of the patella
- •Kellgren-Lawrence radiographic score 0, 1 or 4 in the study knee
- •Symptomatic osteoarthritis of the contralateral knee or of either hip that is not responsive to acetaminophen/paracetamol and/or requires any protocol prohibited therapies
Outcomes
Primary Outcomes
WOMAC (Western Ontario and McMaster Osteoarthritis Index) Pain Subscale Change From Baseline
Time Frame: over 18 weeks (week timepoints 6, 10, 14, and 18)
Pain assessment is made of 5 items; each has 5 possible values 0=none, 1=mild, 2=moderate, 3=severe, 4=extreme. The items are summed for a total range of 0 to 20. Therefore, the pain change from baseline range is -20 to 20. A negative change is a reduction in pain from the baseline pain score. A mixed-effect repeated measures regression model was used to estimate a least square mean for the entire "Measured Time Frame". Change from baseline was the dependent variable. Subject baseline score was a fixed effect covariate. Enrollment site, treatment, visit, and treatment by visit interaction were fixed class effects. Subject was a random effect. A least square mean single point estimate and 95%CI was calculated for the entire "Measured Time Frame" using all data collected at each time point within the "Measured Time Frame".
Secondary Outcomes
- WOMAC (Western Ontario and McMaster Osteoarthritis Index) Pain Subscale Change From Baseline(over 26 weeks (week 6, 10, 14, 18, and 26))
- WOMAC (Western Ontario and McMaster Osteoarthritis Index) Physical Function Subscale Change From Baseline(over 26 weeks (week timepoints 6, 10, 14, 18, and 26))
- Subject Global Assessment Change From Baseline(over 26 weeks (week timepoints 6, 10, 14, 18, and 26))
- WOMAC (Western Ontario and McMaster Osteoarthritis Index) Knee Stiffness Subscale Change From Baseline(over 26 weeks (week timepoints 6, 10, 14, 18, and 26))